PDF
XLS
DOC
DOC
Johnson & Johnson Pricing Transparency Report
View report
Transparency report
Prescription drug net pricing
As net prices decline
Our R&D investments
What we believe
Citations
Fast facts
2022 Executive summary
2022 at a glance
$39 Billion: breaking it down
Rebates, discounts and fees provided to intermediaries
PDABs and UPLs
The 340B program
Archive
Menu
Archive
View report
Transparency report
Prescription drug net pricing
As net prices decline
Our R&D investments
What we believe
Citations
Fast facts
2022 Executive summary
2022 at a glance
$39 Billion: breaking it down
Rebates, discounts and fees provided to intermediaries
PDABs and UPLs
The 340B program
Previous Reports and Additional Resources
Influence of PDABs and UPLs on the State Drug Pricing Ecosystem
Download
The 2021 Janssen U.S. Transparency Report
Download
The 2021 Janssen U.S. Transparency Report Executive Summary
Download
How Insurers Divert Co-Pay Support Meant
for Patients
How Insurers Divert Co-Pay Support Meant for Patients
Download
The 2020 Janssen U.S. Transparency Report
Download
The 2020 Janssen U.S. Transparency Report Executive Summary
Download
2019 Janssen U.S. Transparency Report
Download
2019 Janssen U.S. Transparency Report Executive Summary
Download
2018 Janssen U.S. Transparency Report
Download
2018 Janssen U.S. Transparency Report Executive Summary
Download
2017 Janssen U.S. Transparency Report
Download
2017 Janssen U.S. Transparency Report Executive Summary
Download
2016 Janssen U.S. Transparency Report
Download
2016 Janssen U.S. Transparency Report Executive Summary
Download